Cancer Eye Diseases
Conditions
Interventions
Topical 5 fluorouracil eye drops
Sponsors
St John Eye Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients presenting with symptomatic conjunctival masses that have: 1. Suspicious features of OSSN on clinical examination a. Leukoplakia b. Feeder vessels c. Pigmentation 2. Persistent symptoms despite topical medical therapy a. Redness b. Foreign body sensation c. Blurred vision
Exclusion criteria
Exclusion criteria: 1. Age less than 18 years 2. Pregnant or breastfeeding 3. Previous surgery or topical chemotherapy in the presenting eye 4. Masses with invasion of adjacent structures: forniceal conjunctiva, palpebral conjunctiva, tarsal conjunctiva, lacrimal punctum and canaliculi, plica, caruncle, anterior or posterior eyelid lamellae, eyelid margin, and/or intraocular compartments. 5. Neurological conditions that prevent performing study investigations (AS-OCT, IC, methylene blue stain) 6. Heritable conditions that predispose to conjunctival tumours (Xeroderma pigmentosum and oculocutaneous albinism) 7. The presence of primary acquired melanosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare non-invasive diagnostic methods (cytology, AS-OCT, methylene blue staining) with histology (gold standard) in the diagnosis with OSSN To evaluate the outcomes (success and recurrence rates) with OSSN treatment (medical and surgical) over a 1-year period | — |
Secondary
| Measure | Time frame |
|---|---|
| To identify the characteristics associated with successful OSSN treatment and with OSSN recurrence over a 1-year period To describe the adverse events associated with surgical and medical treatment of OSSN | — |
Countries
South Africa
Contacts
Public ContactRoland Hollhumer
Lecturer
Outcome results
None listed